Founders Fund V Management’s Unity Biotechnology UBX Stock Holding History

Founders Fund V Management’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-49,172	Closed	-$18.7K	–	4
2025 Q2	$18.7K	Hold	49,172	–	–	1.36%	3
2025 Q1	$51.1K	Hold	49,172	–	–	4.78%	3
2024 Q4	$48K	Hold	49,172	–	–	2.85%	3
2024 Q3	$72.3K	Hold	49,172	–	–	12.64%	2
2024 Q2	$66.4K	Hold	49,172	–	–	7.85%	4
2024 Q1	$80.6K	Hold	49,172	–	–	7.38%	4
2023 Q4	$94.9K	Hold	49,172	–	–	10.03%	2
2023 Q3	$118K	Hold	49,172	–	–	14.7%	2
2023 Q2	$125K	Hold	49,172	–	–	10.8%	2
2023 Q1	$80.2K	Sell	49,172 -442,579	-90%	-$1.77M	6.17%	2
2022 Q4	$135K	Buy	491,751 +442,576	+900%	+$1.29M	7.85%	2
2022 Q3	$196K	Hold	49,175	–	–	4.98%	3
2022 Q2	$275K	Hold	49,175	–	–	2.22%	3
2022 Q1	$550K	Hold	49,175	–	–	0.04%	5
2021 Q4	$717K	Hold	49,175	–	–	0.04%	4
2021 Q3	$2.28M	Hold	49,175	–	–	0.78%	4
2021 Q2	$2.28M	Hold	49,175	–	–	0.78%	3
2021 Q1	$2.95M	Hold	49,175	–	–	0.16%	6
2020 Q4	$2.58M	Buy	+49,175	New	+$2.37M	0.66%	5

Other funds holding UBX

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

AIP

Ameritas Investment Partners Lincoln, Nebraska $3.25B AUM 28.52% 1-Year Est. Return

AWM

AllSquare Wealth Management Albany, New York $189M AUM 14.89% 1-Year Est. Return

Founders Fund V Management's UBX Position: Q3 2025 in Review

Founders Fund V Management sold out of Unity Biotechnology (UBX) in Q3 2025, closing a stake of 49,172 shares — an estimated $18.7K sold.

Founders Fund V Management first reported a position in UBX in Q4 2020 and held it in 19 quarters. The position peaked at $2.95M in Q1 2021. 6 funds tracked by Wall St. Rank hold UBX as of Q3 2025.

Founders Fund V Management reported no remaining Unity Biotechnology position as of Q3 2025 after selling out during the quarter.
Founders Fund V Management sold 49,172 Unity Biotechnology shares in Q3 2025, an estimated $18.7K.
Founders Fund V Management first reported a position in Unity Biotechnology in Q4 2020 and held it in 19 quarters.
Founders Fund V Management's Unity Biotechnology position peaked at $2.95M in Q1 2021.
6 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2025.

Based on Founders Fund V Management's 13F filing for Q3 2025, filed 14 Nov 2025.